Click to Share
 

Filter News
Show All Results
News By Country
News By Tag
Nucleic Acids Remove


July 2016
WeTuMoSuSaFrTh
27262524232221

Public Company News

Business Press Releases

Nucleic Acids Press Releases

+ Alert
+ Feed
Exclusive News
Topics Locations Industries Dates

By MoBiTec GmbH
Nucleases are nucleic acid degrading enzymes capable of cleaving the phosphodiester bonds between the nucleotide subunits of its substrate. HS-Nuclease, a broad band nuclease, is an indispensable tool to reduce the viscosity of cell lysates.
12281187
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.
12273825
By Mary Ann Liebert, Inc., publishers
Drugs comprised of single strands of DNA, called aptamers, can bind to targets inside tumor cells causing cell death. But these DNA drugs cannot readily get inside tumor cells on their own.
12254276
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.
By TriLink BioTechnologies, Inc.
TriLink BioTechnologies, Inc. was awarded a Phase I SBIR Grant by the National Institutes of Health to develop an approach to RNA sample preparation for Next Generation Sequencing (NGS) using TriLink's expertise in nucleic acid chemistry.
12084947
By Mary Ann Liebert, Inc., publishers
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease.

All Press Releases

By MoBiTec GmbH
Nucleases are nucleic acid degrading enzymes capable of cleaving the phosphodiester bonds between the nucleotide subunits of its substrate. HS-Nuclease, a broad band nuclease, is an indispensable tool to reduce the viscosity of cell lysates.
12281187
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.
12273825
By Mary Ann Liebert, Inc., publishers
Drugs comprised of single strands of DNA, called aptamers, can bind to targets inside tumor cells causing cell death. But these DNA drugs cannot readily get inside tumor cells on their own.
12254276
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.
By TriLink BioTechnologies, Inc.
Dr. Gerald Zon, noted scientist in the field of nucleic acid research launched a new blog in conjunction with TriLink Biotechnologies. The blog, Zone In with Zon (zon.trilinkbiotech.com), focuses on what's trending in the field of nucleic acids.
By TriLink BioTechnologies, Inc.
TriLink BioTechnologies, Inc. was awarded a Phase I SBIR Grant by the National Institutes of Health to develop an approach to RNA sample preparation for Next Generation Sequencing (NGS) using TriLink's expertise in nucleic acid chemistry.
12084947
By Mary Ann Liebert, Inc., publishers
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease.
12065122
By Mary Ann Liebert, Inc., publishers
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells.
By MarketResearch.com
Molecular diagnostics (MDx) is the fastest growing segment of the in vitro diagnostics industry (IVD).

Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share